

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 49D2022169	(X3) Date Survey Completed 04/01/2026
Name of Provider or Supplier Pariser Dermatology Specialists	Street Address, City, State 3907 Bridge Road, Suite 200, Suffolk, VA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D0000	An announced recertification CLIA survey was conducted at Pariser Dermatology Specialists on April 1, 2026 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Regulations. Pariser Dermatology Specialists was not in compliance with the applicable Conditions and Standards under 42 CFR part 493 CLIA Regulations. Specific deficiencies are as follows:
D5429	<p>MAINTENANCE AND FUNCTION CHECKS CFR(s): 493.1254(a)(1)</p> <p>(a)(1) Maintenance as defined by the manufacturer and with at least the frequency specified by the manufacturer.</p> <p>This STANDARD is not met as evidenced by: Based on a laboratory tour, review of policy and procedures, maintenance logs, and an interview, the laboratory failed to document monthly maintenance performed on the Thermo Scientific Linistat stainer for four (4) months and the Lecia cryostats for seven (7) months of 15 months reviewed. Findings include: 1. During a MOHS laboratory tour at 9:23am on 04/01/2026, the inspector noted 2 Lecia cryostats and 1 automated Thermo Scientific Linistat linear stainer in use for MOHS sample processing. 2. Review of the lab's policy & procedures revealed a maintenance schedule for Stainer cleaning and Cryostat de-contamination defined as monthly. 3. Review of the January 2025 - March 2026 MOHS logs revealed no cryostat monthly maintenance documented in February, June, July, August, September and October of 2025, and January of 2026 (7 of 15 months). 4. Review of the January 2025 - March 2026 H&E (hematoxylin and eosin) maintenance logs revealed no monthly stainer cleaning documented in January, July, and December of 2025, and January of 2026 (4 of 15 months). 5. In an exit interview at 11:45 am on 4/1/26 with the operation managers, and general dermatology clinical supervisor, the findings above were confirmed.</p>

D5477

CONTROL PROCEDURES

CFR(s): 493.1256(e)(4)(g)

(e)(4) Before, or concurrent with the initial use-- (e)(4)(i) Check each batch of media for sterility if sterility is required for testing; (e)(4)(ii) Check each batch of media for its ability to support growth and, as appropriate, select or inhibit specific organisms or produce a biochemical response; and (e)(4)(iii) Document the physical characteristics of the media when compromised and report any deterioration in the media to the manufacturer.

This STANDARD is not met as evidenced by:

Based on a review of lab policy and procedures, Manufacturer's Instructions for use (IFU), quality control (QC) documentation, and interview, the lab failed to perform control testing for growth inhibition on one (1) of four (4) lots of Dermatophyte Testing Medium (DTM) utilized between 01/20/2025 - 11/11/2025 with nine (9) patients tested. Findings include: 1. Review of the lab's DTM Examination policy revealed new lots of DTM media undergo QC testing that includes one positive & one negative control organism to demonstrate growth and inhibition of media. 2. Review of the Remel IFU for DTM revealed "Testing of control organisms should be performed in accordance with established laboratory quality control procedures." 3. Review of the lab's April 2024 through March 2026 DTM QC documentation revealed 4 lots of Remel DTM media utilized in patient testing. Documentation lacked evidence of testing a negative control organism for DTM lot #169319 utilized for patient testing from 01/20/2025 - 11/11/2025. 4. Review of the DTM patient logs indicated 9 patients were tested between 01/20/2025 - 11/11/2025. 5. In an exit interview at 11:45 am on 4/1/26 with the operation managers, Suffolk general dermatology operations manager, general dermatology clinical supervisor, the findings above were confirmed.